stockrowPrecipio, Inc.
PRPO Healthcare Diagnostics & Research
Precipio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.0 million, up 29.8% from fiscal 2024.
- Revenue
- +24.2%
- EPS
- −340.0%
- Free cash flow
- +79.6%
- Total debt
- +47.7%
Quarter to June 2026, against a year earlier
Follow PRPO
Alert me
Precipio, Inc. (PRPO) EV/Sales
As of 5 November 2026, Precipio, Inc. (PRPO) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from −6.3× (May 2015) to 27.7× (January 2015); the current reading is higher than 27% of that period. That is below the Diagnostics & Research industry median of 5.2× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.5× | 262.57% |
| FY2024 | 0.4× | (16.37%) |
| FY2023 | 0.5× | (59.22%) |
| FY2022 | 1.2× | (52.61%) |
| FY2021 | 2.5× | (53.49%) |
| FY2020 | 5.3× | 44.06% |
| FY2019 | 3.7× | 32.94% |
| FY2018 | 2.8× | (43.09%) |
| FY2017 | 4.9× | 1.55% |
| FY2016 | 4.8× | (55.95%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | (6.34%) |
| Mar 2026 | 1.7× | 13.51% |
| Dec 2025 | 1.5× | 19.95% |
| Sep 2025 | 1.2× | 58.88% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| XWEL XWELL, Inc. compare | −0.1× |
| QUCY Quantum Cyber N.V compare | 0.8× |
| MDXH MDxHealth SA compare | 0.8× |
| PRPO Precipio, Inc. | 1.2× |
| NDRA ENDRA Life Sciences Inc. compare | 1.9× |
| TTOO T2 Biosystems, Inc. compare | 6.3× |
| BNR Burning Rock Biotech Limited Sponsored ADR compare | 18.6× |
| MDXHF MedX Health Corp. compare | 29.4× |
| IMDX Insight Molecular Diagnostics Inc. compare | 43.0× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)